Zinger Key Points
- Inspira Technologies integrated an AI-powered oxygenation indicator into its HYLA blood sensor for real-time monitoring of oxygen levels.
- Clinical validation of the enhanced HYLA sensor is underway, with preliminary results expected soon and FDA submission planned for 2H 2025.
On Wednesday, Inspira Technologies OXY B.H.N. Ltd. IINN announced the integration of a next-generation oxygenation indicator into its AI-powered HYLA blood sensor technology.
This technology is designed to enable the rapid detection of critical oxygen-related conditions without the need for intermittent blood draws.
The company says the integration represents a significant enhancement in critical care monitoring.
The technology is designed to provide data through real-time and continuous monitoring of oxygenation therapy, enabling the rapid detection of tissue hypoxia and the early warning of respiratory complications.
The advanced AI-powered system is designed to indicate lung function levels and monitor vital blood parameters, positioning HYLA as a potential game-changer in the $2.5 billion point-of-care testing and arterial blood gas analyzer market.
Clinical validation of the enhanced HYLA blood sensor, with its new oxygenation indicator, is underway at Sheba Medical Center.
The company expects to release preliminary clinical results for the sensor in the near future.
The noninvasive technology utilizes optical sensors and machine-learning algorithms to deliver continuous monitoring of blood parameters and oxygen levels. An FDA submission for regulatory clearance is anticipated for the second half of 2025.
Adding advanced oxygenation monitoring capabilities further strengthens HYLA’s position as a comprehensive blood monitoring solution. Combined with the FDA-cleared INSPIRA ART100 system, this technology aims to provide a more complete approach to patient care by enabling continuous, noninvasive monitoring.
The flagship INSPIRA ART system aims to revolutionize the $19 Billion Mechanical ventilation market and is being designed to elevate and stabilize declining oxygen saturation levels in patients while they are awake and without a ventilator.
Last month, Inspira Technologies announced the development of a modular configuration for its VORTX blood oxygenation delivery technology, designed to enrich small volumes of blood with oxygen and simultaneously remove carbon dioxide to elevate saturation levels to 95% or higher.
Price Action: IINN stock closed at $0.86 on Tuesday.
Read Next:
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
